Tag Archive for: CNS disorders

CONNECTA Therapeutics to Advance CTH120 into Phase II Pediatric Development for Fragile X Syndrome with EIC Accelerator Support

/in

CTH120 is a first-in-class neuroplasticity modulator with strong Phase I safety and tolerability data Awarded a €2.5M European Innovation Council (EIC) Accelerator grant to prepare for Phase II development in pediatric Fragile X Syndrome (FXS) patients CONNECTA leads innovation in neurodevelopmental therapies as a unique European biotech advancing a clinical-stage FXS program Barcelona, Spain – […]

Read more

Novo Holdings participates in $372.5 million Series D financing of MapLight Therapeutics to advance differentiated CNS therapies

/in

Financing to support Phase 2 trials of lead program for schizophrenia and Alzheimer’s disease psychosis, and expansion of CNS pipeline San Francisco, US, 28 July 2025 – Novo Holdings, a leading life science investor, today announced its participation in a $372.5 million Series D financing of MapLight Therapeutics (“MapLight”), a clinical-stage biopharmaceutical company focused on improving […]

Read more

Neuraxpharm expands operations into the Middle East

/in

Brings leading CNS products, including BRIUMVI® (ublituximab), to new territories Dubai, UAE, Barcelona, Spain and Düsseldorf, Germany – 1st October, 2024 – Neuraxpharm Group (Neuraxpharm), a leading European specialty pharmaceutical company focused on the treatment of central nervous system (CNS) disorders, announces the launch of Neuraxpharm Middle East to cover the six members of the Gulf Cooperation […]

Read more

Neuraxpharm expands outside Europe into Brazil and Mexico

/in

Recently acquired Sanofi portfolio products to be combined with acquired Libber Pharma infrastructure to build new affiliate in Brazil Products in Mexico to be distributed through newly established greenfield affiliate  Barcelona and Düsseldorf – July 11, 2023 – Neuraxpharm Group (Neuraxpharm), a leading European specialty pharmaceutical company focused on the treatment of central nervous system (CNS) […]

Read more

Neuraxpharm rebrands Laboratorios Lesvi as Neuraxpharm Pharmaceuticals S.L.

/in

Laboratorios Lesvi is Neuraxpharm’s manufacturing facility for Finished Dosage Forms (FDF) in Spain Barcelona and Dusseldorf – May 4, 2023 – Neuraxpharm Group (Neuraxpharm), the leading European specialty pharmaceutical company focused on the treatment of central nervous system (CNS) disorders, announces that it has rebranded Laboratorios Lesvi to create Neuraxpharm Pharmaceuticals S.L. Read more…

Read more
© Optimum Strategic Communications.